SCHEMBL642106

SCHEMBL642106

[CH2]C(C)C1CCC2OC2(C)C1

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.33
FTH1 P02794 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8776958 0.83 CYP3A4 (0.33) CYP3A4FTH1CYP2C9CYP2C19ALDH1A1
SCHEMBL14183545 0.83 CYP3A4 (0.33) CYP3A4FTH1CYP2C9CYP2C19ALDH1A1
SCHEMBL14183400 0.80 CYP3A4 (0.32) CYP3A4ALDH1A1
SCHEMBL12744539 0.77 CYP3A4 (0.30) CYP3A4
SCHEMBL14183437 0.76
SCHEMBL14183402 0.74 CYP3A4 (0.33) CYP3A4ALDH1A1
SCHEMBL14183547 0.74 CYP3A4 (0.31) CYP3A4
SCHEMBL14183418 0.74
SCHEMBL14183499 0.73 CYP3A4 (0.30) CYP3A4
SCHEMBL14183489 0.73 CYP3A4 (0.30) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200278611-A1 A METHOD OF PREPARING A PLANAR OPTICAL WAVEGUIDE ASSEMBLY DOW SILICONES CORP (US) 2020-09-03 US claimed
US-20140060324-A1 METHOD OF PREPARING GAS SELECTIVE MEMBRANE USING EPOXY-FUNCTIONAL SILOXANES DOW CORNING CORPORATION (US) 2014-03-06 US claimed
EP-3194501-B1 3D PRINTING METHOD UTILIZING A PHOTOCURABLE SILICONE COMPOSITION DOW SILICONES CORP (US) 2024-07-10 EP disclosed
WO-2024145273-A2 N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) 2024-07-04 WO disclosed
EP-4392430-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS Yale University (US) 2024-07-03 EP disclosed
EP-4392168-A1 IONIC LIQUID-BASED COMPOSITE MEMBRANES USING FUNCTIONAL CROSS-LINKERS The Regents of the University of Colorado, a body corporate (US) 2024-07-03 EP disclosed
US-20240181438-A1 UNSYMMETRICAL N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-06-06 US disclosed
CN-118103453-A Silicone-polyolefin hybrid elastomer 陶氏环球技术有限责任公司 2024-05-28 CN disclosed
US-20240165597-A1 STERICALLY HINDERED N-ALIPHATIC N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-05-23 US disclosed
US-20240158580-A1 CURABLE SILICONE COMPOSITION DOW SILICONES CORP (US) 2024-05-16 US disclosed
WO-2024097160-A1 TRANSITION METAL COMPLEXES FOR MRI APPLICATIONS AND METHODS OF USE YALE UNIVERSITY (US) 2024-05-10 WO disclosed
EP-0571965-B1 Curable silicone composition DOW CORNING TORAY SILICONE (JP) 1998-10-21 EP disclosed
EP-0567079-B1 Curable resin composition DOW CORNING TORAY SILICONE (JP) 1997-03-26 EP disclosed
EP-0541988-B1 Organopolysiloxane and method for the preparation thereof DOW CORNING TORAY SILICONE (JP) 1997-03-12 EP disclosed
US-5530075-A CURABLE RESIN, ORGANOPOLYSILOXANE HAVING EPOXY GROUPS DOW CORNING TORAY SILICONE CO., LTD. (JP) 1996-06-25 US disclosed
US-5358983-A Flexible, heat resistance, hardness DOW CORNING TORAY SILICONE CO., LTD. (JP) 1994-10-25 US disclosed
US-5310843-A Organopolysiloxane and method for the preparation thereof DOW CORNING TORAY SILICONE CO., LTD. (JP) 1994-05-10 US disclosed
EP-0571965-A1 Curable silicone composition Dow Corning Toray Silicone Company, Limited (JP) 1993-12-01 EP disclosed
EP-0567079-A1 Curable resin composition Dow Corning Toray Silicone Company, Limited (JP) 1993-10-27 EP disclosed
EP-0541988-A1 Organopolysiloxane and method for the preparation thereof Dow Corning Toray Silicone Company, Limited (JP) 1993-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240181438-A1 UNSYMMETRICAL N-HETEROCYCLIC CARBENE CATALYSTS AND METHODS USING SAME NDC1, NUDC, NSFL1C CYP3A4 408/4885FTH1 1362/4885CYP2C9 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.